Compounded tirzepatide at Forva costs $299 every 4 weeks on a standard 4-week plan (about $324 per calendar month), or as little as $239 every 4 weeks when a 48-week standard plan is paid upfront (about $259 per calendar month). Forva also offers provider-supervised tirzepatide microdose plans starting as low as $139 every 4 weeks (about $151 per calendar month) on a 48-week prepaid plan. Prices include the provider visit, medication if prescribed, shipping, and ongoing provider support.
How much does compounded tirzepatide cost through Forva?
Forva offers standard compounded tirzepatide plans and lower-dose microdose plans, with pricing based on plan type and length.
| Plan | Total paid | Every 4 weeks | About per calendar month |
|---|---|---|---|
| Standard 4-week | $299 | $299 | $324 |
| Standard 12 weeks | $807 | $269 | $291 |
| Standard 24 weeks | $1,554 | $259 | $281 |
| Standard 48 weeks | $2,868 | $239 | $259 |
| Microdose 4-week | $229 | $229 | $248 |
| Microdose 12 weeks | $537 | $179 | $194 |
| Microdose 24 weeks | $954 | $159 | $172 |
| Microdose 48 weeks | $1,668 | $139 | $151 |
The 12-week, 24-week, and 48-week plans are paid upfront. The every-4-weeks figures shown for those plans are the total price divided by the number of 4-week billing cycles in the plan. Forva bills every 4 weeks, which works out to 13 billing cycles a year rather than 12 calendar months.
For standard compounded tirzepatide, the lowest effective cost is $239 every 4 weeks on the 48-week prepaid plan. For a provider-supervised tirzepatide microdose plan, the lowest effective cost is $139 every 4 weeks on the 48-week prepaid plan.
You can review current options on Forva's weight-loss treatment page.
What is a tirzepatide microdose plan?
A tirzepatide microdose plan uses a lower-dose approach that may be prescribed by a licensed provider when medically appropriate.
Microdose treatment is not simply a discounted version of a standard plan. The medication, dose, and treatment approach are determined by the licensed provider based on the patient's medical information.
At Forva, tirzepatide microdose plans range from $229 every 4 weeks on the 4-week plan to an effective $139 every 4 weeks on the 48-week prepaid plan.
As with all Forva GLP-1 treatment, eligibility and prescribing decisions are made by a licensed provider.
What is included in the plan price?
The listed price includes the licensed provider review, compounded tirzepatide if prescribed, shipping, and ongoing provider support.
Forva does not add a separate membership fee to its compounded tirzepatide plans. That matters when comparing online GLP-1 programs because some advertised medication prices do not include every fee involved in treatment.
Forva's compounded GLP-1 plans are self-pay. Insurance is not needed or accepted. Forva accepts FSA and HSA cards, and whether a purchase counts as a qualified expense is determined by the patient's plan administrator.
Treatment begins with a short online medical intake. A licensed provider reviews the patient's information and determines whether treatment is medically appropriate. If prescribed, the medication is prepared by a licensed U.S. compounding pharmacy and shipped discreetly to the patient's door.
Patients can review the full Forva weight-loss process and treatment options before starting.
Do you pay for medication if the provider does not prescribe it?
No. If the licensed provider determines that GLP-1 treatment is not appropriate, the patient is not charged for medication.
The provider, not Forva, makes the individual eligibility and treatment decision. That means completing the online intake does not guarantee that tirzepatide or any other medication will be prescribed.
Patients who are ready to complete the medical intake can start the Forva weight-loss evaluation.
Is compounded tirzepatide the same as Zepbound or Mounjaro?
No. Compounded tirzepatide is not Zepbound, Mounjaro, a generic version of either drug, or an FDA-approved equivalent.
Compounded medications are not FDA-approved. The FDA states that it does not review compounded drugs for safety, effectiveness, or quality before they are marketed. The FDA also distinguishes compounded drugs from FDA-approved generic drugs.
Zepbound is an FDA-approved tirzepatide product with its own prescribing information. Clinical evidence, indications, warnings, and FDA review associated with Zepbound apply to that approved product and should not be transferred to a compounded tirzepatide product.
Forva's compounded medication contains tirzepatide as its active ingredient, but it is not the brand-name product and is not an FDA-approved generic.
Why can compounded tirzepatide pricing differ from brand-name medication pricing?
Compounded medications and FDA-approved brand-name medications move through different manufacturing, regulatory, prescribing, and payment systems, so their prices should not be expected to match.
A compounded drug is prepared by a compounding pharmacy for a patient's prescription rather than sold as an FDA-approved brand-name product. The FDA notes that compounded medications may serve an important medical need in some circumstances, but they do not undergo the same premarket review as FDA-approved drugs.
Forva's prices are self-pay prices for its provider-supervised telehealth program. They include the provider review, medication if prescribed, shipping, and ongoing provider support rather than billing those components separately.
That makes the listed plan price useful when comparing the actual out-of-pocket cost of online GLP-1 programs.
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is not FDA-approved.
The FDA says unapproved GLP-1 products, including compounded semaglutide and tirzepatide, do not undergo its review for safety, effectiveness, or quality before marketing. The FDA recommends that patients obtain prescriptions from licensed healthcare providers and fill them through appropriately licensed pharmacies.
The provider determines whether compounded treatment is medically appropriate for an individual patient. Results vary, and no particular outcome can be guaranteed.
Can you get compounded tirzepatide without insurance?
Yes. Forva's compounded tirzepatide plans are self-pay, so patients do not need insurance to use the program.
The published price is what the plan costs rather than an insurance copay estimate. Standard compounded tirzepatide costs $299 every 4 weeks on the 4-week plan, with prepaid options that work out to $269, $259, or $239 every 4 weeks.
Provider-supervised tirzepatide microdose plans start at $229 every 4 weeks, with prepaid options that work out to $179, $159, or as little as $139 every 4 weeks.
Although Forva does not bill insurance, Forva accepts FSA and HSA cards. Whether a purchase counts as a qualified medical expense is determined by the patient's plan administrator, so patients should check their plan's rules before using those funds.
Forva's compounded GLP-1 service is available in all 50 states, subject to a licensed provider determining that treatment is appropriate.
Patients can read Forva patient reviews or visit the Forva Help Center for more information about the process.
Which tirzepatide plan has the lowest cost every 4 weeks?
The tirzepatide microdose 48-week prepaid plan has the lowest effective cost at $139 every 4 weeks, with $1,668 paid upfront.
Among standard compounded tirzepatide plans, the 48-week prepaid plan has the lowest effective cost at $239 every 4 weeks, with $2,868 paid upfront.
The right plan is not necessarily the longest or lowest-priced option for every patient. Plan length is a financial choice. Whether tirzepatide is appropriate, whether a microdose approach is appropriate, and what treatment a patient should receive if prescribed are medical decisions made by a licensed provider.
Forva's pricing is designed to make the full compounded-plan cost visible before a patient begins the provider-supervised process, without adding a separate membership fee later.
This article is for general information and is not medical advice. Eligibility and treatment decisions are made by a licensed provider.